Navigation Links
Rempex Announces Series B Financing of Up to $67.5 Million
Date:11/9/2011

SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Rempex Pharmaceuticals, Inc. today announced that it has completed the initial closing of a Series B financing.  New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street Partners in committing to a total of $67.5 million for this round.  This financing, together with a previous Series A round, brings the total financing commitment for Rempex to $76 million since the company's founding in June 2011.

Rempex is focused on developing internally discovered new treatments for resistant gram-negative infections.  The company expects to file a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for its first product candidate in the second half of 2012 and an Investigational New Drug Application (IND) with the FDA for its second product candidate in the first quarter of 2012.

"We are very pleased to have been able to attract such a strong group of experienced healthcare investors," stated Daniel Burgess, President and Chief Executive Officer of Rempex.  "This financing gives us the resources to rapidly advance our development programs towards commercialization at a time when the need for new treatments for resistant gram-negative infections has become critical."

About Rempex Pharmaceuticals

Rempex Pharmaceuticals, Inc. is a biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company was founded to acquire all the assets, including financial and human resources, not associated with Aeroquin™ from Mpex Pharmaceuticals, Inc.  Aptalis Holdings Inc. acquired Mpex and its lead product candidate, Aeroquin™, earlier this year.  Company website: www.rempexpharma.com


'/>"/>
SOURCE Rempex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amylin Pharmaceuticals Announces Date and Time Change to Previously Announced Presentation at the Credit Suisse 2011 Healthcare Conference
2. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
3. China Sky One Medical Announces Third Quarter 2011 Results
4. China Information Technology, Inc. Announces Third Quarter 2011 Results
5. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
8. MedBox Announces Ticker Symbol Change
9. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
10. ECRI Institute Announces its Top 10 Health Technology Hazards for 2012
11. Echo Therapeutics Announces Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... May 31, 2016 ... Assembly zur Eliminierung von viraler Hepatitis    ... historische Verpflichtung eingegangen, virale Hepatitis bis 2030 zu ... World Health Assembly haben sich die Staaten einstimmig ... Hepatitis (Global Viral Hepatitis Strategy) zu verabschieden, was ...
(Date:5/30/2016)... 2016 Transparency Market Research has ... Systems Market - Global Industry Analysis, Size, Share, Growth, ... report, the global advanced (3D/4D) visualization systems market was ... anticipated to expand at a CAGR of 6.4% from ... 2024. Advanced (3D/4D) visualization systems have propelled ...
(Date:5/30/2016)... , May 30, 2016 ... "Healthcare Analytical Testing Services Market by Type (Stability, ... Services), by End User (Pharmaceutical Companies, Medical Device ... MarketsandMarkets, The market witnessed healthy growth during the ... a CAGR of 11.3% between 2016 and 2021 ...
Breaking Medicine Technology:
(Date:5/31/2016)... MN (PRWEB) , ... May 31, 2016 , ... DDL, ... the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO 594-2 ... common means of achieving a leak-free connection between two medical devices (e.g. a syringe ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the multiple awards ... is home to Ontario’s leading day spa and one of Canada’s few accredited 5 ... a unique concept to combine spa services with hair and beauty services ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education Foundation (OREF) ... David G. Lewallen, MD, began his term as president in March, succeeding John J. ... is OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, corporate development, ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 Inc. , Each ... series of research reports evaluating these innovative vendors and their products and services. ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Super Powder, a ... to on the go individuals and dedicated athletes, continues to transform the nutritional supplement ... with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, ...
Breaking Medicine News(10 mins):